The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 772K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

8 articles for JN Hamblin


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
30
Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors.EBI
Glaxosmithkline
2
Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza.EBI
Glaxosmithkline
34
Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode.EBI
Glaxosmithkline R&D
30
Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma.EBI
Ontario Institute For Cancer Research
16
Discovery of Potent, Efficient, and Selective Inhibitors of Phosphoinositide 3-Kinase δ through a Deconstruction and Regrowth Approach.EBI
Glaxosmithkline R&D
39
Optimization of Orally Bioavailable PI3Kδ Inhibitors and Identification of Vps34 as a Key Selectivity Target.EBI
Glaxosmithkline
68
Disubstituted 1, 2, 4-triazine compoundBDB
Mitsubishi Tanabe Pharma
28
Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design.BDB
Banyu Tsukuba Research Institute